Putting our results into a purely clinical context, the lesson learnt from this experience was to always bear in mind the chance of BM development in patients with HER2 + CRC: thus, symptoms suggesting cerebral localizations should be carefully explored in this special population. The gene discussed is ERBB2; the disease is colorectal carcinoma.